Continued Treatment for Participants Enrolled in Studies of BXQ-350
A legfontosabb adatok
- Ki végzi
- Bexion Pharmaceuticals, Inc.
- Hol
- Cincinnati, Columbus és Lexington (Egyesült Államok)Mind a 3 helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 1. fázis
- Résztvevők
- 5 fő vett részt
- Kezdés
- 2020. jún. 8.
- Befejezés
- 2024. szept. 23.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- BXQ-350
- A regiszteradat frissítve
- 2024. december 20.
- Miért állt le
- Bexion Pharmaceuticals no longer has open studies in which subjects would be eligible to rollover and continue treatment under the BXQ-350.AE protocol. Therefore, no additional subjects will be enrolled in this trial.
Ki vehet részt
- Életkor
- 1 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 2 feltétel megnézéseKevesebb
Ki vehet részt
- Each subject must meet the following criteria:; Has participated in and completed all protocol-specified treatments through the required study observation period or time of closure for a prior Bexion-sponsored BXQ-350 clinical study; Has completed the End of Study visit of the prior Bexion-sponsored BXQ-350 clinical study; Did not meet any treatment discontinuation criteria of the original prior Bexion- sponsored BXQ-350 clinical study; Investigator opinion indicates that continued treatment with BXQ-350 is clinically appropriate for the subject; Provide signed, written informed consent prior to the initiation of any study-specific procedures (Consent from Guardians for minor children and patient assent according to Institution and Institutional Review Board (IRB) standards); Have a negative serum pregnancy test result within 28 days prior to the first continuing treatment assessment for females of child bearing potential (FCBP); not applicable to subjects who are unable to become pregnant, including those with tubal ligation, bilateral oophorectomy and/or hysterectomy); FCBP and male subjects whose sexual partner(s) are FCBP must agree to abstain from heterosexual activity or use a double barrier method of contraception (e.g., condom and occlusive cap with spermicide) or highly effective contraception (intrauterine device or system, established hormonal contraceptive methods on a stable dose from the time of the last menstrual cycle, or vasectomized partner with confirmed azoospermia) from the time of study entry to 1 month after the last day of treatment
Ki nem vehet részt
- Subjects must not meet any of the following criteria:; Has any ongoing adverse event that could impact tolerability to BXQ-350; Receiving any other non-BXQ-350 study treatment modalities with curative intent, including investigational products other than BXQ-350; Are pregnant or nursing (lactating), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum human chorionic gonadotropin (hCG) laboratory test
Helyszínek itt: Egyesült Államok
- University of Cincinnati Barrett CenterCincinnati, Egyesült Államok
- The Ohio State University Comprehensive Cancer CenterColumbus, Egyesült Államok
- University of Kentucky/Markey Cancer CenterLexington, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a study to allow continued treatment for participants enrolled in studies of BXQ-350. This study is intended only for those who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study. The additional treatment is optional and voluntary.
A vizsgálat csoportja
- Continued TreatmentA vizsgált kezelés
Subjects who have completed the required study observation period or are still on treatment upon the closure of their respective BXQ-350 clinical study, and who are judged by the Investigator to benefit from continued treatment with BXQ-350. Treatment will begin after completion of the End of Study visit of the prior BXQ-350 clinical study. The established safe dose of BXQ-350 from previous adult and pediatric phase 1 studies is 2.4 mg/kg and 3.2 mg/kg respectively once every 28 days (± 3 days). BXQ-350 will be administered intravenously at the same dose level and frequency the subject was receiving at the end of the prior BXQ-350 clinical study. Subjects receiving a reduced dose at the end of the prior BXQ-350 clinical study due to toxicity may continue to receive a reduced dose.
Kezelés: BXQ-350
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Open-Label, Multi-Center, Rollover Study to Provide Continued Treatment Access for Participants Enrolled in Studies of BXQ-350
- A regiszteradat frissítve
- 2024. december 20.